Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 448 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Beating the Heat with Beets July 31, 2020 Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... November 20, 2020 Texting May Help Reduce Disparities in Colorectal Cancer Screening March 19, 2021 FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... December 7, 2021 Load more HOT NEWS FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz Jimmy Carter Signed This Treaty Demanding An End To Violence Against...
